Survodutide Peptide research-grade
Survodutide Peptide

Survodutide Peptide

$182.00

Research-grade Survodutide Peptide for laboratory investigation. For Research Use Only. Not for human use.

For Research Use Only — Not for Human Consumption
Free shipping on all orders over $200 (US)

  • 99% Purity – Third-Party Tested
  • Fast & Reliable Shipping
Guaranteed Checkout

Accepted Payment Methods

For Research Use Only. Not for human use.

Survodutide Peptide research-grade

Overview

Survodutide Peptide is supplied as a research-grade catalog material for controlled laboratory investigation.

Laboratories choose this item when protocols need clear identification, consistent labeling, and documentation suitable for reproducible experimental workflows.

Catalog packaging and research-use labeling help purchasing and bench teams keep procurement records aligned with the physical vial.

Research Context for Survodutide Peptide

Work involving Survodutide Peptide typically focuses on in vitro systems, assay development, and mechanistic model studies.

Teams confirm lot details before setup so conditions stay traceable across repeats and collaborative sites.

Published literature can inform starting ranges for related experimental designs. Each laboratory should still validate performance with its own instruments, plates, and detection chemistry.

Pilot runs are useful before committing larger plate sets, especially when detection chemistry or incubation windows are being optimized.

Documented Attributes

Key catalog attributes for this material include:

  • Research-grade material intended for laboratory investigation only
  • Catalog labeling aligned with research procurement channels
  • Suitable for method development and comparative assay workflows
  • Documentation packages available where provided for the listed lot

Laboratory Handling Notes

Receiving and Identity Checks

Before opening a vial of Survodutide Peptide, confirm the physical label against the purchase order and packing list.

Retain outer packaging until identity checks are complete, and report damaged seals to purchasing before experimental work continues.

Reconstitution and Aliquoting

Handle this material according to institutional SOPs for weighing, reconstitution, aliquoting, and storage.

Record lot identifiers in laboratory notebooks before reconstitution. Verify solvent compatibility and storage temperature against your validated process.

Prepare assay buffers and consumables before opening the vial to reduce hold time. Keep unused aliquots labeled with date, solvent, and concentration for later repeats.

Chain of Custody

Keep chain-of-custody notes with inventory checks when material moves between freezers or benches.

Use dedicated spatulas and clean balances to avoid cross-contamination between catalog items. Schedule thaw cycles intentionally rather than repeated freeze-thaw of the same aliquot.

Secondary containment trays reduce spill risk during multi-step reconstitution. Cold-chain interruptions should be noted even when the vial remains sealed.

Why Laboratories Source Survodutide Peptide

Procurement and research teams often select this catalog item because it supports:

  • Clear research-use labeling for compliance-aligned purchasing
  • Consistent product identification across multi-lot studies
  • Fit for reference, screening, and mechanistic laboratory models
  • Straightforward catalog support for planning and documentation

Study Planning and Quality Documentation

Before starting experimental work with Survodutide Peptide, review any COA or quality files provided with the shipment.

Align your protocol with institutional research requirements and keep use within the labeled research context.

File catalog documentation with the study records at receipt. These steps help keep experiments comparable over time when using Survodutide Peptide in sequential study phases.

Method Development Tips

Method development often begins with small pilot plates before larger screening panels.

Document buffer lots, incubation times, and detection settings alongside the material lot number.

If results diverge from historical baselines, re-check reconstitution volume and storage history first. Shared equipment logs help explain variance when multiple operators run the same protocol.

Inventory and Training

Update digital inventory immediately after opening a new lot of Survodutide Peptide.

Training new staff on labeling conventions reduces mix-ups across similar catalog SKUs. When transferring methods between sites, share both the written SOP and the lot metadata package.

Dispose of residual solutions according to institutional chemical hygiene rules. Do not repurpose research materials for any non-laboratory application.

Periodic inventory reconciliation keeps expired or depleted lots from entering active workflows. For related catalog options, browse adjacent research categories on this site after confirming your assay needs.

For Research Use Only. Not for human or animal use. Not intended to diagnose, treat, cure, or prevent any disease.

Peptide Research

For Research Use Only. Not for human use.

PubMed (NIH/NLM) records related to this compound for laboratory literature review. Inclusion does not imply suitability for any use beyond controlled research. Each note below is a research-framed summary using compliance-safe wording.

Showing 32 PubMed records. Displaying 10 per page.

  1. Sanyal AJ et al. (2024). Laboratory research record on Survodutide [PMID: 38847460]

    PubMed laboratory record discussing Survodutide in a research context. Review the full methods and limitations on PubMed; research use only.

  2. le Roux CW et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for metabolic research models: a… [PMID: 38330987]

    Laboratory literature summary: Glucagon and GLP-1 receptor dual agonist survodutide for metabolic research models: a randomised, double-blind, control arm-controlled,…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  3. Blüher M et al. (2024). Laboratory research record on Survodutide [PMID: 38095657]

    PubMed laboratory record discussing Survodutide in a research context. Review the full methods and limitations on PubMed; research use only.

  4. Lawitz EJ et al. (2024). Observed endpoints, tolerability and pharmacokinetics of survodutide, a… [PMID: 38857788]

    Laboratory literature summary: observed endpoints, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  5. le Roux CW et al. (2026). Survodutide Once Weekly for the investigation of Adults with metabolic research models [PMID: 42253238]

    Laboratory literature summary: Survodutide Once Weekly for the investigation of Adults with metabolic research models. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  6. Kosiborod MN et al. (2024). Survodutide for the investigation of metabolic research models: Rationale and Design… [PMID: 39453356]

    Laboratory literature summary: Survodutide for the investigation of metabolic research models: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  7. le Roux CW et al. (2026). Laboratory research record on Survodutide [PMID: 41187967]

    PubMed laboratory record discussing Survodutide in a research context. Review the full methods and limitations on PubMed; research use only.

  8. Wharton S et al. (2026). Laboratory research record on Survodutide [PMID: 41216778]

    PubMed laboratory record discussing Survodutide in a research context. Review the full methods and limitations on PubMed; research use only.

  9. Thomas L et al. (2024). The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for… [PMID: 38560764]

    Laboratory literature summary: The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for laboratory candidate selection. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  10. Kaplan LM et al. (2026). Laboratory research record on Survodutide [PMID: 42252333]

    PubMed laboratory record discussing Survodutide in a research context. Review the full methods and limitations on PubMed; research use only.

  11. Wharton S et al. (2025). Laboratory research record on Survodutide [PMID: 39495965]

    PubMed laboratory record discussing Survodutide in a research context. Review the full methods and limitations on PubMed; research use only.

  12. Kaya E et al. (2024). Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction [PMID: 39663847]

    Laboratory literature summary: Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  13. Platz E et al. (2026). Survodutide for the investigation of metabolic research models: Baseline… [PMID: 41329105]

    Laboratory literature summary: Survodutide for the investigation of metabolic research models: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  14. Arun AJ et al. (2025). Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care [PMID: 40963161]

    Laboratory literature summary: Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  15. Augustin R et al. (2025). Novel NPY2R agonist BI 1820237 provides synergistic anti-metabolic research models… [PMID: 40619099]

    Laboratory literature summary: Novel NPY2R agonist BI 1820237 provides synergistic anti-metabolic research models observed endpoints when combined with the GCGR/GLP-1R…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  16. Yathindra MR et al. (2026). A review of survodutide: a new dual acting agonist [PMID: 41855048]

    Laboratory literature summary: A review of survodutide: a new dual acting agonist. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  17. Dutta D et al. (2025). Laboratory research record on Survodutide [PMID: 40688625]

    PubMed laboratory record discussing Survodutide in a research context. Review the full methods and limitations on PubMed; research use only.

  18. Xiao YJ et al. (2025). Observed endpoints and laboratory profile of survodutide on glycemic control and… [PMID: 40922121]

    Laboratory literature summary: observed endpoints and laboratory profile of survodutide on glycemic control and body-composition research in adults: A systematic…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  19. Zimmermann T et al. (2026). Survodutide acts through circumventricular organs in the brain and activates neuronal… [PMID: 41638399]

    Laboratory literature summary: Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with feeding-behavior endpoints regulation. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  20. Awad AA et al. (2025). Laboratory research record on Survodutide [PMID: 40557198]

    PubMed laboratory record discussing Survodutide in a research context. Review the full methods and limitations on PubMed; research use only.

  21. Klein T et al. (2024). Laboratory research record on Survodutide [PMID: 37330144]

    PubMed laboratory record discussing Survodutide in a research context. Review the full methods and limitations on PubMed; research use only.

  22. le Roux CW et al. (2025). Laboratory research record on Survodutide [PMID: 39821928]

    PubMed laboratory record discussing Survodutide in a research context. Review the full methods and limitations on PubMed; research use only.

  23. Yokote K et al. (2026). Survodutide for the investigation of metabolic research models Disease in Japanese… [PMID: 42219222]

    Laboratory literature summary: Survodutide for the investigation of metabolic research models Disease in Japanese Participants: Rationale, Design and Baseline…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  24. Ekinci EI et al. (2026). Laboratory research record on Survodutide [PMID: 42331726]

    PubMed laboratory record discussing Survodutide in a research context. Review the full methods and limitations on PubMed; research use only.

  25. Almandoz JP et al. (2026). How does survodutide work? Plain language review of a potential new medication for… [PMID: 42254697]

    Laboratory literature summary: How does survodutide work? Plain language review of a potential new medication for metabolic research models and liver disease. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  26. Wan H et al. (2024). Laboratory research record on Survodutide [PMID: 39508238]

    PubMed laboratory record discussing Survodutide in a research context. Review the full methods and limitations on PubMed; research use only.

  27. le Roux CW et al. (2025). Laboratory research record on Survodutide [PMID: 39582349]

    PubMed laboratory record discussing Survodutide in a research context. Review the full methods and limitations on PubMed; research use only.

  28. Wang B et al. (2026). Operationalising disease modification in metabolic research models trials: A blueprint… [PMID: 41424209]

    Laboratory literature summary: Operationalising disease modification in metabolic research models trials: A blueprint based on the SYNCHRONIZE-1 survodutide study. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  29. Blüher M et al. (2024). Laboratory research record on Survodutide [PMID: 38349400]

    PubMed laboratory record discussing Survodutide in a research context. Review the full methods and limitations on PubMed; research use only.

  30. Long F et al. (2026). Hepatic GCGR is required for the superior body-composition research and metabolic… [PMID: 41388343]

    Laboratory literature summary: Hepatic GCGR is required for the superior body-composition research and metabolic effects of a structurally related analogue of the dual…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  31. Vinton TY (2025). Survodutide: a novel peptide for investigation of metabolic research models and… [PMID: 40557206]

    Laboratory literature summary: Survodutide: a novel peptide for investigation of metabolic research models and metabolic diseases. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  32. Rubino DM et al. (2026). Optimization of research subjects and site engagement in the SYNCHRONIZE™ phase 3… [PMID: 41704810]

    Laboratory literature summary: Optimization of research subjects and site engagement in the SYNCHRONIZE™ phase 3 laboratory trial program for survodutide in metabolic…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

Browse the full PubMed index: PubMed search.

Additional information

Weight .125 lbs
Dimensions 8 × 7 × .5 in
Size: No selection

5mg, 10mg

Keep lyophilized peptides sealed in their original vial, protected from light and humidity, and store at -4°F or colder for optimal long-term stability in research settings; short-term refrigeration at around 39°F suffices for immediate use within weeks, though freezer storage maximizes integrity across extended research timelines.

Frequently Asked Questions

What is Survodutide peptide?

Survodutide is a synthetic peptide studied in research laboratories for its role in glucagon and GLP-related receptor signaling pathways.

What is Survodutide used for in research?

Survodutide is used in research laboratories to investigate peptide-receptor interactions, metabolic signaling, and endocrine pathway activity. It is not approved for human use.

Is Survodutide Peptide approved or intended for human use?

No. Survodutide is strictly intended for research purposes only and is not approved by the FDA for human use.

Is Survodutide Peptide FDA-approved for medical or clinical use?

No. Survodutide is not approved by the U.S. Food and Drug Administration for any medical, therapeutic, or diagnostic use.

In what form is Survodutide supplied?

Survodutide is supplied as a lyophilized (freeze-dried) peptide powder for use in controlled research laboratories.

How should Survodutide be stored?

Store sealed, lyophilized peptides protected from light and humidity at -4°F or colder; refrigeration (~39°F) is suitable for short-term use

What vial sizes are available for Survodutide?

Survodutide is available in multiple vial sizes (e.g., 5mg, 10mg).

Is Survodutide Peptide sold as a prescription product?

No prescription is required; however, it is sold strictly for research use only.

How is Survodutide shipped?

Orders are processed and shipped using secure, protective packaging to maintain product integrity during transit. For more info, visit: https://www.nationwidepeptides.com/shipping-and-payments

How can I verify Survodutide purity and quality?

Product quality is supported through third-party laboratory testing and Certificates of Analysis (COA), confirming purity and batch consistency. For more info, visit: https://www.nationwidepeptides.com/coa/